Hubbry Logo
Thyroid diseaseThyroid diseaseMain
Open search
Thyroid disease
Community hub
Thyroid disease
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Thyroid disease
Thyroid disease
Thyroid disease
View on Wikipedia
from Wikipedia
Thyroid disease
An illustration of goiter, a type of thyroid disease
SpecialtyEndocrinology, medical genetics Edit this on Wikidata

Thyroid disease is a medical condition that affects the structure and/or function of the thyroid gland. The thyroid gland is located at the front of the neck and produces thyroid hormones[1] that travel through the blood to help regulate many other organs, meaning that it is an endocrine organ. These hormones normally act in the body to regulate energy use, infant development, and childhood development.[2]

There are five general types of thyroid disease, each with their own symptoms. A person may have one or several different types at the same time. The five groups are:

  1. Hypothyroidism (low function) caused by not having enough free thyroid hormones[2]
  2. Hyperthyroidism (high function) caused by having too many free thyroid hormones[2]
  3. Structural abnormalities, most commonly a goiter (enlargement of the thyroid gland)[2]
  4. Tumors which can be benign (not cancerous) or cancerous[2]
  5. Abnormal thyroid function tests without any clinical symptoms (subclinical hypothyroidism or subclinical hyperthyroidism).[2]

In the US, hypothyroidism and hyperthyroidism were respectively found in 4.6 and 1.3% of the >12y old population (2002).[3]

In some types, such as subacute thyroiditis or postpartum thyroiditis, symptoms may go away after a few months and laboratory tests may return to normal.[4] However, most types of thyroid disease do not resolve on their own. Common hypothyroid symptoms include fatigue, low energy, weight gain, inability to tolerate the cold, slow heart rate, dry skin and constipation.[5] Common hyperthyroid symptoms include irritability, anxiety, weight loss, fast heartbeat, inability to tolerate the heat, diarrhea, and enlargement of the thyroid.[6] Structural abnormalities may not produce symptoms; however, some people may have hyperthyroid or hypothyroid symptoms related to the structural abnormality or notice swelling of the neck.[7] Rarely goiters can cause compression of the airway, compression of the vessels in the neck, or difficulty swallowing.[7] Tumors, often called thyroid nodules, can also have many different symptoms ranging from hyperthyroidism to hypothyroidism to swelling in the neck and compression of the structures in the neck.[7]

Diagnosis starts with a history and physical examination. Screening for thyroid disease in patients without symptoms is a debated topic although commonly practiced in the United States.[8] If dysfunction of the thyroid is suspected, laboratory tests can help support or rule out thyroid disease. Initial blood tests often include thyroid-stimulating hormone (TSH) and free thyroxine (T4).[9] Total and free triiodothyronine (T3) levels are less commonly used.[9] If autoimmune disease of the thyroid is suspected, blood tests looking for Anti-thyroid autoantibodies can also be obtained. Procedures such as ultrasound, biopsy and a radioiodine scanning and uptake study may also be used to help with the diagnosis, particularly if a nodule is suspected.[2]

Thyroid diseases are highly prevalent worldwide,[10][11][12] and treatment varies based on the disorder. Levothyroxine is the mainstay of treatment for people with hypothyroidism,[13] while people with hyperthyroidism caused by Graves' disease can be managed with iodine therapy, antithyroid medication, or surgical removal of the thyroid gland.[14] Thyroid surgery may also be performed to remove a thyroid nodule or to reduce the size of a goiter if it obstructs nearby structures or for cosmetic reasons.[14]

Signs and symptoms

[edit]

Symptoms of the condition vary with type: hypo- vs. hyperthyroidism, which are further described below.

Possible symptoms of hypothyroidism are:[15][16]

Possible symptoms of hyperthyroidism are:[17]

Note: certain symptoms and physical changes can be seen in both hypothyroidism and hyperthyroidism —fatigue, fine / thinning hair, menstrual cycle irregularities, muscle weakness / aches (myalgia), and different forms of myxedema.[18][19]

Diseases

[edit]

Low function

[edit]
Main article: Hypothyroidism

Hypothyroidism is a state in which the body is not producing enough thyroid hormones, or is not able to respond to / utilize existing thyroid hormones properly. The main categories are:

High function

[edit]
Exophthalmos is the eye bulging that may be seen with Graves Disease, one of the major causes of hyperthyroidism
Main article: Hyperthyroidism

Hyperthyroidism is a state in which the body is producing too much thyroid hormone. The main hyperthyroid conditions are:

Structural abnormalities

[edit]
Endemic goiter

Tumors

[edit]

Medication side effects

[edit]

Certain medications can have the unintended side effect of affecting thyroid function. While some medications can lead to significant hypothyroidism or hyperthyroidism and those at risk will need to be carefully monitored, some medications may affect thyroid hormone lab tests without causing any symptoms or clinical changes, and may not require treatment.[citation needed] The following medications have been linked to various forms of thyroid disease:

Pathophysiology

[edit]

Most thyroid disease in the United States stems from a condition where the body's immune system attacks itself. In other instances, thyroid disease comes from the body trying to adapt to environmental conditions like iodine deficiency or to new physiologic conditions like pregnancy.

Autoimmune Thyroid Disease

[edit]

Autoimmune thyroid disease is a general category of disease that occurs due to the immune system targeting its own body. It is not fully understood why this occurs, but it is thought to be partially genetic as these diseases tend to run in families.[9] In one of the most common types, Graves' Disease, the body produces antibodies against the TSH receptor on thyroid cells.[4] This causes the receptor to activate even without TSH being present and causes the thyroid to produce and release excess thyroid hormone (hyperthyroidism).[4] Another common form of autoimmune thyroid disease is Hashimoto's thyroiditis where the body produces antibodies against different normal components of the thyroid gland, most commonly thyroglobulin, thyroid peroxidase, and the TSH receptor.[9] These antibodies cause the immune system to attack the thyroid cells and cause inflammation (lymphocytic infiltration) and destruction (fibrosis) of the gland.[9]

Goiter

[edit]

Goiter is the general enlargement of the thyroid that can be associated with many thyroid diseases. The main reason this happens is because of increased signaling to the thyroid by way of TSH receptors to try to make it produce more thyroid hormone.[9] This causes increased vascularity and increase in size (hypertrophy) of the gland.[9] In hypothyroid states or iodine deficiency, the body recognizes that it is not producing enough thyroid hormone and starts to produce more TSH to help stimulate the thyroid to produce more thyroid hormone.[9] This stimulation causes the gland to increase in size to increase production of thyroid hormone. In hyperthyroidism caused by Graves' Disease or toxic multinodular goiter, there is excess stimulation of the TSH receptor even when thyroid hormone levels are normal.[4] In Graves' Disease this is because of an autoantibodies (Thyroid Stimulating Immunoglobulins) which bind to and activate the TSH receptors in place of TSH while in toxic multinodular goiter this is often because of a mutation in the TSH receptor that causes it to activate without receiving a signal from TSH.[4] In more rare cases, the thyroid may become enlarged because it becomes filled with thyroid hormone or thyroid hormone precursors that it is unable to release or because of congenital abnormalities or because of increased intake of iodine from supplementation or medication.[9]

Pregnancy

[edit]

There are many changes to the body during pregnancy. One of the major changes to help with the development of the fetus is the production of human chorionic gonadotropin (hCG). This hormone, produced by the placenta, has similar structure to TSH and can bind to the maternal TSH receptor to produce thyroid hormone.[23] During pregnancy, there is also an increase in estrogen which causes the mother to produce more thyroxine binding globulin, which is what carries most of the thyroid hormone in the blood.[24] These normal hormonal changes often make pregnancy look like a hyperthyroid state but may be within the normal range for pregnancy, so it necessary to use trimester specific ranges for TSH and free T4.[23][24] True hyperthyroidism in pregnancy is most often caused by an autoimmune mechanism from Graves' Disease.[23] New diagnosis of hypothyroidism in pregnancy is rare because hypothyroidism often makes it difficult to become pregnant in the first place.[23] When hypothyroidism is seen in pregnancy, it is often because an individual already has hypothyroidism and needs to increase their levothyroxine dose to account for the increased thyroxine binding globulin present in pregnancy.[23]

Diagnosis

[edit]

Diagnosis of thyroid disease depends on symptoms and whether or not a thyroid nodule is present. Most patients will receive a blood test. Others might need an ultrasound, biopsy or a radioiodine scanning and uptake study.

Blood tests

[edit]
Overview of the thyroid system and the various hormones involved.

Thyroid function tests

[edit]
Further information: Thyroid function tests

There are several hormones that can be measured in the blood to determine how the thyroid gland is functioning. These include the thyroid hormones triiodothyronine (T3) and its precursor thyroxine (T4), which are produced by the thyroid gland. Thyroid-stimulating hormone (TSH) is another important hormone that is secreted by the anterior pituitary cells in the brain. Its primary function is to increase the production of T3 and T4 by the thyroid gland.

The most useful marker of thyroid gland function is serum thyroid-stimulating hormone (TSH) levels. TSH levels are determined by a classic negative feedback system in which high levels of T3 and T4 suppress the production of TSH, and low levels of T3 and T4 increase the production of TSH. TSH levels are thus often used by doctors as a screening test, where the first approach is to determine whether TSH is elevated, suppressed, or normal.[25]

  • Elevated TSH levels can signify inadequate thyroid hormone production (hypothyroidism)
  • Suppressed TSH levels can point to excessive thyroid hormone production (hyperthyroidism)

Because a single abnormal TSH level can be misleading, T3 and T4 levels must be measured in the blood to further confirm the diagnosis. When circulating in the body, T3 and T4 are bound to transport proteins. Only a small fraction of the circulating thyroid hormones are unbound or free, and thus biologically active. T3 and T4 levels can thus be measured as free T3 and T4, or total T3 and T4, which takes into consideration the free hormones in addition to the protein-bound hormones. Free T3 and T4 measurements are important because certain drugs and illnesses can affect the concentrations of transport proteins, resulting in differing total and free thyroid hormone levels. There are differing guidelines for T3 and T4 measurements.

  • Free T4 levels should be measured in the evaluation of hypothyroidism, and low free T4 establishes the diagnosis. T3 levels are generally not measured in the evaluation of hypothyroidism.[13]
  • Free T4 and total T3 can be measured when hyperthyroidism is of high suspicion as it will improve the accuracy of the diagnosis. Free T4, total T3 or both are elevated and serum TSH is below normal in hyperthyroidism. If the hyperthyroidism is mild, only serum T3 may be elevated and serum TSH can be low or may not be detected in the blood.[14]
  • Free T4 levels may also be tested in patients who have convincing symptoms of hyper- and hypothyroidism, despite a normal TSH.

Antithyroid antibodies

[edit]

Autoantibodies to the thyroid gland may be detected in various disease states. There are several anti-thyroid antibodies, including anti-thyroglobulin antibodies (TgAb), anti-microsomal/anti-thyroid peroxidase antibodies (TPOAb), and TSH receptor antibodies (TSHRAb).[13]

  • Elevated anti-thryoglobulin (TgAb) and anti-thyroid peroxidase antibodies (TPOAb) can be found in patients with Hashimoto's thyroiditis, the most common autoimmune type of hypothyroidism. TPOAb levels have also been found to be elevated in patients who present with subclinical hypothyroidism (where TSH is elevated, but free T4 is normal), and can help predict progression to overt hypothyroidism. The American Association Thyroid Association thus recommends measuring TPOAb levels when evaluating subclinical hypothyroidism or when trying to identify whether nodular thyroid disease is due to autoimmune thyroid disease.[19]
  • When the etiology of hyperthyroidism is not clear after initial clinical and biochemical evaluation, measurement of TSH receptor antibodies (TSHRAb) can help make the diagnosis. In Graves' disease, TSHRAb levels are elevated as they are responsible for activating the TSH receptor and causing increased thyroid hormone production.[18]

Other markers

[edit]
  • There are two markers for thyroid-derived cancers.
    • Thyroglobulin (TG) levels can be elevated in well-differentiated papillary or follicular adenocarcinoma. It is often used to provide information on residual, recurrent or metastatic disease in patients with differentiated thyroid cancer. However, serum TG levels can be elevated in most thyroid diseases. Routine measurement of serum TG for evaluation of thyroid nodules is therefore currently not recommended by the American Thyroid Association.[26]
    • Elevated calcitonin levels in the blood have been shown to be associated with the rare medullary thyroid cancer. However, the measurement of calcitonin levels as a diagnostic tool is currently controversial due to falsely high or low calcitonin levels in a variety of diseases other than medullary thyroid cancer.[26][27]
  • Very infrequently, TBG and transthyretin levels may be abnormal; these are not routinely tested.
  • To differentiate between different types of hypothyroidism, a specific test may be used. Thyrotropin-releasing hormone (TRH) is injected into the body through a vein. This hormone is naturally secreted by the hypothalamus and stimulates the pituitary gland. The pituitary responds by releasing thyroid-stimulating hormone (TSH). Large amounts of externally administered TRH can suppress the subsequent release of TSH. This amount of release-suppression is exaggerated in primary hypothyroidism, major depression, cocaine dependence, amphetamine dependence and chronic phencyclidine abuse. There is a failure to suppress in the manic phase of bipolar disorder.[28]

Ultrasound

[edit]

Many people may develop a thyroid nodule at some point in their lives. Although many who experience this worry that it is thyroid cancer, there are many causes of nodules that are benign and not cancerous. If a possible nodule is present, a doctor may order thyroid function tests to determine if the thyroid gland's activity is being affected. If more information is needed after a clinical exam and lab tests, medical ultrasonography can help determine the nature of thyroid nodule(s). There are some notable differences in typical benign vs. cancerous thyroid nodules that can particularly be detected by the high-frequency sound waves in an ultrasound scan. The ultrasound may also locate nodules that are too small for a doctor to feel on a physical exam, and can demonstrate whether a nodule is primarily solid, liquid (cystic), or a mixture of both. It is an imaging process that can often be done in a doctor's office, is painless, and does not expose the individual to any radiation.[29]

The main characteristics that can help distinguish a benign vs. malignant (cancerous) thyroid nodule on ultrasound are as follows:[30]

Possible thyroid cancer More likely benign
irregular borders smooth borders
hypoechoic (less echogenic than the surrounding tissue) hyperechoic
incomplete "halo" spongiform appearance
significant intranodular / central blood flow by power Doppler marked peripheral blood flow
microcalcifications larger, broad calcifications (note: these can be seen in medullary thyroid cancer)
nodule appears more tall than wide on transverse study "comet tail" artifact as sound waves bounce off intranodular colloid
documented progressive increase in size of nodule on ultrasound

Although ultrasonography is a very important diagnostic tool, this method is not always able to separate benign from malignant nodules with certainty. In suspicious cases, a tissue sample is often obtained by biopsy for microscopic examination.

Radioiodine scanning and uptake

[edit]
Five scintigrams taken from thyroids with different syndromes: A) normal thyroid, B) Graves' disease, diffuse increased uptake in both thyroid lobes, C) Plummer's disease, D) Toxic adenoma, E) Thyroiditis.

Thyroid scintigraphy, in which the thyroid is imaged with the aid of radioactive iodine (usually iodine-123, which does not harm thyroid cells, or rarely, iodine-131),[31] is performed in the nuclear medicine department of a hospital or clinic. Radioiodine collects in the thyroid gland before being excreted in the urine. While in the thyroid, the radioactive emissions can be detected by a camera, producing a rough image of the shape (a radioiodine scan) and tissue activity (a radioiodine uptake) of the thyroid gland.

A normal radioiodine scan shows even uptake and activity throughout the gland. Irregular uptake can reflect an abnormally shaped or abnormally located gland, or it can indicate that a portion of the gland is overactive or underactive. For example, a nodule that is overactive ("hot") -- to the point of suppressing the activity of the rest of the gland—is usually a thyrotoxic adenoma, a surgically curable form of hyperthyroidism that is rarely malignant. In contrast, finding that a substantial section of the thyroid is inactive ("cold") may indicate an area of non-functioning tissue, such as thyroid cancer.

The amount of radioactivity can be quantified and serves as an indicator of the metabolic activity of the gland. A normal quantitation of radioiodine uptake demonstrates that about 8-35% of the administered dose can be detected in the thyroid 24 hours later. Overactivity or underactivity of the gland, as may occur with hyperthyroidism or hypothyroidism, is usually reflected in increased or decreased radioiodine uptake. Different patterns may occur with different causes of hypo- or hyperthyroidism.

Biopsy

[edit]

A medical biopsy refers to the obtaining of a tissue sample for examination under the microscope or other testing, usually to distinguish cancer from noncancerous conditions. Thyroid tissue may be obtained for biopsy by fine needle aspiration (FNA) or by surgery.[citation needed]

Fine needle aspiration has the advantage of being a brief, safe, outpatient procedure that is safer and less expensive than surgery and does not leave a visible scar. Needle biopsies became widely used in the 1980s, though it was recognized that the accuracy of identification of cancer was good, but not perfect. The accuracy of the diagnosis depends on obtaining tissue from all of the suspicious areas of an abnormal thyroid gland. The reliability of fine needle aspiration is increased when sampling can be guided by ultrasound, and over the last 15 years, this has become the preferred method for thyroid biopsy in North America.[32][citation needed]

Treatment

[edit]

Medication

[edit]

Levothyroxine is a stereoisomer of thyroxine (T4) which is degraded much more slowly and can be administered once daily in patients with hypothyroidism.[13] Natural thyroid hormone from pigs is sometimes also used, especially for people who cannot tolerate the synthetic version. Hyperthyroidism caused by Graves' disease may be treated with the thioamide drugs propylthiouracil, carbimazole or methimazole, or rarely with Lugol's solution. Additionally, hyperthyroidism and thyroid tumors may be treated with radioactive iodine. Ethanol injections for the treatment of recurrent thyroid cysts and metastatic thyroid cancer in lymph nodes can also be an alternative to surgery.[citation needed]

Surgery

[edit]

Thyroid surgery is performed for a variety of reasons. A nodule or lobe of the thyroid is sometimes removed for biopsy or because of the presence of an autonomously functioning adenoma causing hyperthyroidism. A large majority of the thyroid may be removed (subtotal thyroidectomy) to treat the hyperthyroidism of Graves' disease, or to remove a goiter that is unsightly or impinges on vital structures.[citation needed]

A complete thyroidectomy of the entire thyroid, including associated lymph nodes, is the preferred treatment for thyroid cancer. Removal of the bulk of the thyroid gland usually produces hypothyroidism unless the person takes thyroid hormone replacement. Consequently, individuals who have undergone a total thyroidectomy are typically placed on thyroid hormone replacement (e.g. levothyroxine) for the remainder of their lives. Higher than normal doses are often administered to prevent recurrence.[citation needed]

If the thyroid gland must be removed surgically, care must be taken to avoid damage to adjacent structures, the parathyroid glands and the recurrent laryngeal nerve. Both are susceptible to accidental removal and/or injury during thyroid surgery.[citation needed]

The parathyroid glands produce parathyroid hormone (PTH), a hormone needed to maintain adequate amounts of calcium in the blood. Removal results in hypoparathyroidism and a need for supplemental calcium and vitamin D each day. In the event that the blood supply to any one of the parathyroid glands is endangered through surgery, the parathyroid gland(s) involved may be re-implanted in surrounding muscle tissue.

The recurrent laryngeal nerves provide motor control for all external muscles of the larynx except for the cricothyroid muscle, which also runs along the posterior thyroid. Accidental laceration of either of the two or both recurrent laryngeal nerves may cause paralysis of the vocal cords and their associated muscles, changing the voice quality. A 2019 systematic review concluded that the available evidence shows no difference between visually identifying the nerve or utilizing intraoperative neuroimaging during surgery, when trying to prevent injury to recurrent laryngeal nerve during thyroid surgery.[33]

Radioiodine

[edit]

Radioiodine therapy with iodine-131 can be used to shrink the thyroid gland (for instance, in the case of large goiters that cause symptoms but do not harbor cancer—after evaluation and biopsy of suspicious nodules has been done), or to destroy hyperactive thyroid cells (for example, in cases of thyroid cancer). The iodine uptake can be high in countries with iodine deficiency, but low in iodine sufficient countries. To enhance iodine-131 uptake by the thyroid and allow for more successful treatment, TSH is raised prior to therapy in order to stimulate the existing thyroid cells. This is done either by withdrawal of thyroid hormone medication or injections of recombinant human TSH (Thyrogen),[31] released in the United States in 1999. Thyrogen injections can reportedly boost uptake up to 50-60%. Radioiodine treatment can also cause hypothyroidism (which is sometimes the end goal of treatment) and, although rare, a pain syndrome (due to radiation thyroiditis).[34]

Epidemiology

[edit]

In the United States, autoimmune inflammation is the most common form of thyroid disease while worldwide hypothyroidism and goiter due to dietary iodine deficiency is the most common.[35][4] According to the American Thyroid Association in 2015, approximately 20 million people in the United States alone are affected by thyroid disease.[11][36] Hypothyroidism affects 3-10% percent of adults, with a higher incidence in women and the elderly.[37][38][39] An estimated one-third of the world's population currently lives in areas of low dietary iodine levels. In regions of severe iodine deficiency, the prevalence of goiter is as high as 80%.[40] In areas where iodine-deficiency is not found, the most common type of hypothyroidism is an autoimmune subtype called Hashimoto's thyroiditis, with a prevalence of 1-2%.[40] As for hyperthyroidism, Graves' disease, another autoimmune condition, is the most common type with a prevalence of 0.5% in males and 3% in females.[41] Although thyroid nodules are common, thyroid cancer is rare. Thyroid cancer accounts for less than 1% of all cancer in the UK, though it is the most common endocrine tumor and makes up greater than 90% of all cancers of the endocrine glands.[40]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Thyroid disease

View on Grokipedia
from Grokipedia
Thyroid disease refers to a group of disorders affecting the gland, a small butterfly-shaped endocrine organ located in the lower front of the neck that produces hormones such as thyroxine (T4) and triiodothyronine (T3), which are essential for regulating , energy generation, growth, development, and the function of nearly every organ in the body. These conditions disrupt normal hormone production or gland structure, leading to either insufficient () or excessive () thyroid hormone levels, as well as structural abnormalities like goiter (enlargement of the gland), nodules (lumps within the gland), (inflammation), and . Common causes include autoimmune disorders such as for and for , along with , medications, radiation exposure, or genetic factors. Autoimmune disorders, such as , are the leading cause of globally, while remains a major contributor in endemic regions, particularly for goiter; in iodine-sufficient areas, autoimmune etiologies predominate. Globally, thyroid diseases are highly prevalent, affecting an estimated 5% of the population with (including up to an additional 5% undiagnosed cases) and 0.2%–1.4% with overt , rising to about 2.5% when including subclinical cases among adults. Women are disproportionately impacted, with prevalence rates 5–10 times higher than in men, and rates increase with age, exceeding 5% in those over 60 in many regions. Thyroid nodules are also common, with a lifetime risk of 5–10% and detectable goiter or nodules in about 15% of adults in some populations. Symptoms of thyroid disease vary by type and severity but often involve systemic effects due to the hormones' broad influence; hypothyroidism typically presents with fatigue, weight gain, cold intolerance, constipation, dry skin, and depression, while hyperthyroidism may cause weight loss, heat intolerance, rapid heartbeat, anxiety, tremors, and diarrhea. Untreated, these conditions can lead to serious complications, including cardiovascular disease, osteoporosis, infertility, and increased mortality risk. Diagnosis relies on clinical evaluation, blood tests measuring thyroid-stimulating hormone (TSH), free T4, and free T3 levels, and imaging or biopsy for structural issues. Treatment is tailored to the specific disorder and may include levothyroxine replacement for hypothyroidism, antithyroid drugs, radioactive iodine ablation, or surgery for hyperthyroidism, with regular monitoring to normalize hormone levels.

Anatomy and Physiology

Thyroid gland structure

The thyroid gland is a butterfly-shaped endocrine organ located in the anterior , positioned anterior to the trachea and overlying the C5 to T1 vertebral levels within the middle compartment of the , bounded anteriorly by the strap muscles and posteriorly by the deep cervical . It consists of two symmetrical lobes, a right and a left, connected by a narrow that crosses the anterior surface of the trachea at the level of the second and third tracheal rings. The gland is anchored to the trachea via the Berry and may include a pyramidal lobe or of Zuckerkandl extending superiorly from the in some individuals. The thyroid's is derived from and comprises follicular units surrounded by a capsule that extends septa into the gland to form lobules. Histologically, it features spherical follicles lined by a simple of cuboidal follicular cells that vary in height—squamous when inactive and columnar when active—resting on a . These follicles contain a central colloid-filled lumen composed of , an iodinated stored for hormone synthesis. Interspersed among the follicular cells are parafollicular (C) cells, which are large, pale-staining, polyhedral cells located between the follicular epithelium and the basement membrane, not extending to the follicular lumen; these cells originate from the ultimobranchial body and produce calcitonin. Blood supply to the thyroid gland is provided primarily by the , the first branch of the , which supplies the upper poles and via branches such as the cricothyroid artery, and the inferior thyroid artery, the third branch of the , which supplies the lower poles and parathyroids. These arteries anastomose bilaterally to ensure robust dual . An accessory arises in approximately 10% of cases from variable origins, such as the brachiocephalic trunk, to supplement the supply. Venous drainage occurs via the superior and middle thyroid veins into the and the into the brachiocephalic veins. Lymphatic drainage from the thyroid follows patterns critical for understanding metastatic spread in , with initial drainage to prelaryngeal, pretracheal, and paratracheal nodes, and further to lower deep cervical nodes; the and inferior lobes particularly drain to paratracheal nodes, while superior poles favor prelaryngeal routes. The gland is closely related to surrounding structures, including the recurrent laryngeal nerves posterolaterally, the parathyroid glands posteriorly, and the laterally.

Hormone production and regulation

The thyroid gland synthesizes primarily in the form of thyroxine (T4) and triiodothyronine (T3) within the follicular lumen. , essential for hormone production, is actively transported into thyroid follicular cells via the sodium- (NIS), a plasma membrane glycoprotein that uses the sodium gradient established by the Na+/K+-ATPase to mediate a 2 Na+:1 I- stoichiometry, concentrating up to 20-40 times higher than in plasma. NIS expression and activity are primarily regulated by (TSH), ensuring adequate availability for hormone synthesis. Thyrocytes produce (Tg), a large precursor synthesized on ribosomes and secreted into the follicular lumen, where it serves as the scaffold for formation. Iodide is oxidized by (TPO) in the presence of to form reactive iodine, which undergoes organification by iodinating specific residues on Tg to produce monoiodotyrosine (MIT) and diiodotyrosine (DIT). The , also catalyzed by TPO, links two DIT residues to form T4 or one MIT and one DIT to form T3, with these s remaining bound to Tg for storage in the . Upon stimulation by TSH, is endocytosed, and lysosomal enzymes cleave Tg to release T4 (about 80% of secreted ) and T3 (about 20%), which are then transported into the bloodstream via the monocarboxylate transporter 8 (MCT8). Most circulating T4 serves as a , converted peripherally to the more active T3 by . Type 1 (D1), expressed mainly in the liver, , and , performs outer-ring deiodination to convert T4 to T3 and contributes to about 20-30% of serum T3 levels while also recycling iodide. Type 2 (D2), found in the , pituitary, , and , locally generates T3 from T4 to maintain intracellular levels, accounting for 70-80% of T3. In contrast, type 3 (D3), predominant in fetal tissues, , and certain adult regions, inactivates T4 by inner-ring deiodination to reverse T3 (rT3) and T3 to 3,3'-T2, protecting tissues from excess exposure. In circulation, over 99% of thyroid hormones are bound to transport proteins, with only the free fraction being biologically active. (TBG), the primary carrier, binds approximately 70-75% of T4 and T3 with high affinity (association constant ~10^10 M^{-1} for T4), while (TTR) binds 15-20% of T4 and less than 1% of T3 (association constant ~2 \times 10^8 M^{-1} for T4), and binds the remainder (10-15% of T4, 25-30% of T3) with lower affinity (association constant ~1.5 \times 10^6 M^{-1} for T4). These proteins modulate hormone delivery to tissues and protect against rapid clearance. Hormone production and secretion are tightly regulated by the hypothalamic-pituitary-thyroid (HPT) axis. The secretes (TRH), which stimulates the to release TSH; TSH binds to receptors on thyrocytes, activating adenylate cyclase and cAMP pathways to upregulate NIS, TPO, Tg synthesis, iodide uptake, and release. Circulating T3 and T4 exert negative feedback by inhibiting TRH and TSH secretion at the and pituitary, respectively, maintaining . In healthy adults, the thyroid produces approximately 90-120 \mu g of T4 and 6-8 \mu g of T3 daily, requiring about 150 \mu g of iodine intake to support this synthesis, as each T4 molecule incorporates four iodine atoms and T3 three. The gland concentrates 70-80% of total body iodine (15-20 mg) to meet these demands.

Clinical Presentation

Hypothyroidism symptoms

Hypothyroidism manifests through a range of symptoms resulting from reduced thyroid hormone levels, which slow metabolic processes across multiple body systems. These symptoms can develop gradually and vary in severity, often mimicking other conditions, but collectively point to underactive thyroid function. Common symptoms include profound fatigue, where individuals experience persistent tiredness that interferes with daily activities despite adequate rest. Weight gain occurs due to slowed and fluid retention, even without changes in diet or exercise. Patients often report cold intolerance, feeling unusually sensitive to low temperatures. Gastrointestinal effects manifest as constipation from decreased gut motility. Skin and hair changes include dry skin and hair loss, with brittle, thinning hair and rough, scaly skin. Cardiovascular signs feature , a slowed heart rate that may lead to reduced cardiac output. , characterized by non-pitting , presents as puffy, doughy swelling in the face, hands, and legs due to mucopolysaccharide accumulation in the . Neurological examination may reveal a prolonged relaxation phase in deep tendon reflexes, reflecting delayed muscle response. Cognitive effects encompass depression, memory impairment, and slowed thinking, contributing to difficulties in concentration and mental processing. Reproductive issues include menstrual irregularities such as heavy or prolonged periods in women, along with infertility in both sexes due to hormonal disruptions. In severe, untreated cases, myxedema coma can occur, a life-threatening emergency marked by , , and , often accompanied by altered mental status and organ failure. In pediatric cases, particularly , symptoms lead to cretinism, featuring severe developmental delays, intellectual disability, stunted physical growth, and motor deficits if untreated in early infancy.

Hyperthyroidism symptoms

Hyperthyroidism, characterized by excessive production of , leads to a hypermetabolic state that manifests in a wide array of symptoms affecting multiple organ systems. Common early signs include unintentional despite an increased , as the accelerated burns calories at a higher rate. Heat and excessive sweating (diaphoresis) are also frequent, resulting from heightened and . Cardiovascular symptoms are prominent, with (rapid heartbeat) and often reported due to the stimulatory effects of on the heart. Irregular heart rhythms, such as , can occur, particularly in older adults, increasing the risk of . Nervous system involvement produces tremors, typically fine and affecting the hands or fingers, alongside anxiety, , and , reflecting the influence on the . Gastrointestinal disturbances include more frequent bowel movements or , stemming from enhanced gut motility. Musculoskeletal effects encompass proximal , which may impair daily activities, and an elevated risk of due to accelerated bone turnover and reduced bone mineral density. An enlarged gland, or goiter, is often palpable as swelling at the base of the . In cases associated with autoimmune processes like , the most common cause of , additional manifestations may appear. Ocular symptoms include (bulging eyes), , and a characteristic stare from eyelid retraction, arising from inflammation of orbital tissues. Rare skin changes, such as —a thickened, discolored area on the shins—can also occur due to deposition. These extrathyroidal features highlight the systemic autoimmune nature of the condition.

Structural abnormality symptoms

Structural abnormalities in the thyroid gland, such as goiters and nodules, can lead to symptoms arising from mechanical compression or distortion of surrounding structures, rather than alterations in hormone production. These manifestations often result from the physical enlargement or irregular growth of the gland, which may press on the , trachea, or adjacent nerves. Common presentations include neck swelling, which is frequently the initial noticeable sign, creating a visible or palpable mass at the base of the neck. Goiters, characterized by diffuse or nodular enlargement of the thyroid, can cause compressive symptoms when sufficiently large. Dysphagia, or difficulty swallowing, occurs due to pressure on the , while dysphonia, a change in voice quality, may arise from compression of the trachea or . Additional effects include a sensation of choking or tightness in the neck, particularly during swallowing or neck movement. In severe cases, tracheal compression can lead to or wheezing, though this is less common in non-substernal goiters. Thyroiditis, an inflammatory condition, often presents with thyroid enlargement that can be either painless or painful. In , the gland becomes tender and swollen, accompanied by localized pain that may radiate to the jaw or ears. Painless thyroiditis, such as silent or postpartum variants, typically involves a nontender enlargement without significant discomfort from the swelling itself. These changes contribute to a feeling of fullness in the neck but are distinguished from compressive issues by their inflammatory origin. Hoarseness is a key symptom when structural abnormalities involve the , which runs close to the thyroid gland. Enlargement from goiters or masses can compress or stretch this nerve, leading to unilateral vocal cord paralysis and altered voice production. This hoarseness is often persistent and may worsen with gland growth, prompting evaluation for nerve entrapment. Thyroid nodules, as discrete lumps within the gland, primarily cause symptoms if they grow large enough to exert compressive effects. Large nodules (>3-4 cm) may produce , neck pressure, or a sensation (lump in the throat), similar to goiter-related issues. While most nodules are , functional ones rarely contribute to endocrine symptoms, but the focus here remains on mechanical impacts like airway narrowing in oversized cases. Massive goiters, often weighing over 200 grams, heighten the risk of severe compressive symptoms, including significant respiratory distress from or narrowing. Patients may experience (difficulty breathing when lying flat) or exertional dyspnea, alongside prominent cosmetic concerns from the visible deformity. These large enlargements can also lead to venous congestion, causing plethora in extreme retrosternal extensions. Multinodular goiters feature multiple irregular lumps that create an uneven, bosselated contour, often palpable as distinct nodules under the skin. These can produce localized symptoms if dominant nodules enlarge, and in some instances, autonomous nodules within the multinodular structure may drive uneven growth patterns. The irregular lumps contribute to cosmetic dissatisfaction and intermittent compressive discomfort, particularly with flexion. Symptoms from such goiters occasionally overlap with those of , such as unexplained hoarseness, necessitating further investigation.

Types of Thyroid Disorders

Hypothyroidism

Hypothyroidism is a condition characterized by insufficient production of by the , leading to a slowdown in and various systemic effects. It is one of the most common endocrine disorders, affecting approximately 4.6% of the U.S. population aged 12 years and older, with higher in women and older adults. The disorder can manifest in overt or subclinical forms and arises from disruptions in thyroid hormone synthesis, release, or regulation. While symptoms such as fatigue, weight gain, and cold intolerance may occur, they are addressed elsewhere in this entry. Hypothyroidism is classified into primary, secondary, and tertiary types based on the level of dysfunction in the hypothalamic-pituitary-thyroid axis. Primary , the most common form, results from intrinsic gland failure, accounting for over 99% of cases in iodine-sufficient regions. Secondary hypothyroidism stems from disorders that reduce (TSH) production, while tertiary hypothyroidism involves hypothalamic dysfunction leading to insufficient . Common causes of primary hypothyroidism include autoimmune destruction via , which is the leading etiology in developed countries; surgical removal of the thyroid; and treatment with radioactive iodine for , which induces permanent hypothyroidism in 80-90% of patients within months to years. In regions with , such as parts of Central and , inadequate iodine intake remains the predominant cause, contributing to endemic goiter and hypothyroidism with prevalence rates exceeding 5-10% in affected populations. Subclinical hypothyroidism represents a milder variant, defined by elevated serum TSH levels with normal free thyroxine (T4) concentrations, often serving as a precursor to overt disease. It affects about 4-10% of the general population, particularly women over 60, and may progress to clinical in 2-5% of cases annually without intervention. Untreated carries significant complications, including increased risk of due to , , and ; infertility through disrupted and menstrual irregularities; and, in severe cases, , a life-threatening marked by , , and multi-organ failure with mortality rates up to 40%. , present at birth due to thyroid , dyshormonogenesis, or maternal factors, affects 1 in 2,000-4,000 newborns globally. Universal , implemented since the 1970s using blood TSH measurements, enables early detection and replacement therapy, resulting in near-normal neurocognitive and physical development outcomes in over 90% of treated infants, preventing and growth stunting.

Hyperthyroidism

Hyperthyroidism is a condition characterized by the overproduction of by the , leading to a state of thyrotoxicosis that accelerates and affects multiple organ systems. It most commonly arises from autoimmune processes, nodular thyroid disease, or , with accounting for 60-80% of cases in iodine-sufficient regions. This disorder is more prevalent in women and can occur at any age, though it peaks between 20 and 40 years. The primary subtypes include , in which circulating autoantibodies stimulate the (TSH) receptor to promote excessive hormone synthesis; , involving multiple autonomously functioning nodules that produce independently of TSH regulation, often in older adults or iodine-deficient areas; and toxic adenoma, a solitary hyperfunctioning nodule driven by somatic mutations leading to unchecked hormone secretion. Subclinical represents a milder form, defined by suppressed TSH levels with normal free thyroxine (T4) and (T3) concentrations, which may progress to overt disease or persist asymptomatically, particularly in the elderly. Iatrogenic can result from excessive exogenous administration, mimicking endogenous overproduction and suppressing TSH. Triggers for hyperthyroidism onset or exacerbation include psychosocial stress, which may precipitate through immune dysregulation; , a known that increases severity and relapse rates, particularly in men; and the , during which immune rebound can initiate autoimmune thyroid overactivity or leading to transient hyperthyroidism. Complications encompass , a rare but life-threatening exacerbation with systemic decompensation including fever, , and altered mental status; accelerated bone loss contributing to , especially in postmenopausal women due to enhanced ; and cardiovascular risks such as and from chronic and increased myocardial oxygen demand. In , eye disease manifests as orbital inflammation and tissue expansion, causing proptosis, periorbital edema, and potential vision impairment in up to one-third of patients, often independently of thyroid hormone levels.

Goiter and thyroid nodules

A goiter refers to an abnormal enlargement of the gland, which can be classified as diffuse or nodular based on its structure. Diffuse goiter involves uniform swelling of the entire gland, often resulting from compensatory due to chronic stimulation, such as in or autoimmune conditions. In contrast, nodular goiter features discrete lumps or masses within the gland, which may evolve from a diffuse form over time. Endemic goiter, a subtype of diffuse or nodular goiter, arises primarily from in regions with low dietary iodine intake, leading to impaired hormone synthesis and subsequent glandular to maintain hormone production. Thyroid nodules are discrete lesions within the thyroid parenchyma, categorized as solitary or multinodular depending on their number and distribution. Solitary nodules occur as isolated masses, while multinodular goiters involve multiple nodules, often developing asymmetrically and potentially causing compressive symptoms like or dyspnea if large. Nodules are further distinguished by function: hot or hyperfunctioning nodules actively produce excess thyroid hormone independently of (TSH) regulation, appearing as areas of increased uptake on ; cold or nonfunctioning nodules do not produce hormone and show reduced or absent uptake. Most nodules are benign, with common etiologies including cysts (fluid-filled sacs), hemorrhage (intrathyroidal bleeding into a nodule), and (such as in ). Autonomously functioning nodules, particularly hot ones, carry a of progressing to overt , known as toxic nodules, due to unchecked secretion that suppresses TSH and leads to thyrotoxicosis. This autonomy often stems from somatic mutations in TSH receptor genes, allowing nodules to grow and function independently, with approximately 5-10% of longstanding nodules developing this feature over time. Evaluation of nodules for potential relies on clinical and characteristics, such as greater than 4 cm, which raises concern regardless of cytology in some guidelines, and microcalcifications, indicative of possible psammoma bodies or dystrophic changes. Other worrisome features include irregular margins and hypoechogenicity on , prompting further assessment to differentiate benign from suspicious lesions. Historically, goiter prevalence was dramatically reduced through initiatives like salt iodization programs, which began in the early . , mandatory iodization of table salt introduced in led to a sharp decline in endemic goiter rates, from over 40% in some regions to less than 5% within decades, serving as a model for global efforts that have prevented millions of cases worldwide.

Thyroid cancer

Thyroid cancer refers to a group of malignancies originating in the gland, with differentiated cancers comprising the majority of cases and generally carrying a favorable . Papillary is the most common subtype, accounting for about 80% to 85% of all cancers, and it typically grows slowly with a high cure rate following treatment. Follicular , representing 10% to 15% of cases, arises from follicular cells and shares similar indolent behavior but may more readily spread via the bloodstream to distant sites like the lungs or bones. Medullary , which originates from parafollicular C cells, makes up 2% to 5% of cancers and can be sporadic or hereditary. Anaplastic , although rare (less than 2% of cases), is extremely aggressive, often presenting in older adults and leading to rapid progression and poor outcomes. Key risk factors for include exposure to , especially during childhood, which is strongly linked to the development of papillary and follicular subtypes through mechanisms like DNA damage in cells. For medullary thyroid carcinoma, genetic predisposition plays a prominent role, with mutations in the RET proto-oncogene causing up to 25% of cases, often in association with (MEN2) syndromes or familial medullary . Other factors, such as female sex and certain genetic syndromes, modestly elevate risk across subtypes, but radiation and RET mutations remain the most established. Staging for employs the American Joint Committee on Cancer (AJCC) TNM system, which evaluates size and extent (T), regional involvement (N), and distant (M), with age-specific adjustments for differentiated cancers and separate schemas for medullary and anaplastic types. , particularly in the central neck, occurs in up to 50% of papillary cases at and upregulates the N stage, influencing surgical extent and recurrence risk. varies markedly by : differentiated cancers (papillary and follicular) have five-year relative rates exceeding 98% for localized disease and over 90% overall, reflecting effective therapies and indolent biology. is around 80% to 90% at five years for localized tumors, while anaplastic has a median of months, with five-year rates below 10%. The incidence of thyroid cancer has risen steadily since the 1990s, tripling in some populations, primarily due to of subclinical papillary microcarcinomas detected incidentally via and other imaging during evaluations for unrelated conditions. Notable therapeutic advances include FDA approvals in 2020 for targeted inhibitors such as and pralsetinib, which specifically inhibit RET alterations in advanced or medullary and differentiated cancers, improving in these challenging cases. The 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated provide updated recommendations based on recent advances in molecular causes and treatment options.

Drug-induced thyroid dysfunction

Drug-induced thyroid dysfunction encompasses a range of hypo- and hyperthyroid states triggered by medications or toxins that interfere with thyroid hormone synthesis, , or . These disruptions often stem from the drug's direct effects on thyroid follicular cells, iodine handling, or autoimmune modulation, affecting up to 20% of patients on certain long-term therapies. Unlike primary thyroid disorders, iatrogenic cases are typically reversible upon drug discontinuation, though monitoring is essential to prevent complications such as arrhythmias or . Amiodarone, an rich in iodine, frequently induces thyroid abnormalities due to its high iodine load (37% by weight) and inhibition of enzymes, leading to altered T4-to-T3 conversion. (AIH) occurs in 5-20% of treated patients, particularly in iodine-sufficient regions, presenting with elevated TSH and low free T4 levels; it is more common in women and those with preexisting autoimmune . (AIT), seen in 2-10% of cases, is classified into type 1 (iodine-induced hyperthyroidism in nodular glands) and type 2 (destructive from direct toxicity), with type 2 predominating in iodine-replete areas. Diagnosis involves color-flow Doppler to differentiate types, and treatment may require drug cessation or in severe AIT. Lithium, used in management, impairs thyroid hormone release and iodination, resulting in in 10-20% of long-term users, often subclinical with goiter formation. This effect is mediated by lithium's interference with signaling and TSH receptor expression, increasing the risk in women over 50 and those with positive antithyroid antibodies. is rarer (less than 5%), but goiter prevalence can reach 40-50% after years of therapy. Baseline TSH screening and monitoring every 6-12 months are recommended, with supplementation for overt cases. Interferon-alpha (IFN-α), employed in hepatitis C and treatment, triggers thyroid by upregulating expression and production, leading to destructive or in 5-15% of patients. Up to 40% develop thyroid antibodies during therapy, with being the most common outcome (10%), though occurs in 3-5%. Risk factors include preexisting and female sex; prospective studies show peak incidence within 6 months of initiation. Discontinuation of IFN-α often resolves dysfunction, but persistent may require long-term . Immune checkpoint inhibitors (ICIs), such as PD-1 inhibitors (e.g., nivolumab, ), have surged in use for since 2015, causing thyroid immune-related adverse events (irAEs) in 10-20% of recipients through T-cell mediated . develops in 10-15%, often following a transient hyperthyroid phase from follicular destruction, while isolated affects 5-10%; combination ICI therapy elevates risks to 20-30%. These events typically onset within 3-6 months and correlate with better oncologic outcomes, possibly indicating robust immune activation. involves baseline TSH/thyroid antibody testing and monitoring every 4-6 weeks during therapy. Iodine-containing agents, including radiographic contrast media and antiseptics like , can precipitate thyroid dysfunction via excess iodide load. The Wolff-Chaikoff effect, a protective inhibition of thyroid synthesis, causes transient in 1-5% of exposed individuals, particularly those with underlying disease or neonates; it usually resolves within 48 hours via "escape" mechanisms. In contrast, the induces in iodine-deficient patients with nodular goiters, occurring in up to 10% after high-dose exposure, due to unchecked synthesis post-adaptation failure. Pre-exposure screening is advised for at-risk groups, such as those with multinodular goiter. Antithyroid drugs like methimazole (MMI), used to treat , paradoxically cause —a severe —in 0.2-0.5% of patients, typically within the first 3 months of therapy. This idiosyncratic reaction involves immune-mediated , presenting with fever, , or ; absolute below 500/μL confirms diagnosis. Immediate MMI discontinuation and (G-CSF) support recovery, which occurs in most cases within 1-2 weeks, though rechallenge is contraindicated. on symptom vigilance is a key monitoring strategy. Tyrosine kinase inhibitors (TKIs), such as and in cancer therapy, disrupt function primarily through (VEGF) inhibition, causing in 20-50% of users by impairing thyroid perfusion and hormone synthesis. is less common (5-10%), often subclinical. Onset averages 2-6 months into treatment, with higher risks for multi-targeted TKIs; thyroid function worsens with prolonged use. Dose-dependent effects necessitate TSH monitoring at baseline, monthly during , and every 3 months thereafter, with replacement as needed. Recovery from drug-induced thyroid dysfunction varies by agent: amiodarone and lithium effects often reverse within 3-6 months post-discontinuation, though AIT type 2 may persist longer; ICI-related hypothyroidism is frequently permanent in 50-70% of cases due to glandular destruction. Guidelines from the American Thyroid Association recommend baseline for high-risk drugs, followed by TSH assessments every 3-6 months or upon symptoms like or . In cancer patients on TKIs or ICIs, endocrine consultation is advised for grade 2+ toxicities to balance oncologic benefits against thyroid risks.

Pathophysiology

Autoimmune processes

Autoimmune processes in thyroid disease primarily involve dysregulation of the , leading to the production of autoantibodies and infiltration of inflammatory cells into the thyroid gland, which disrupts normal thyroid function. These mechanisms are central to conditions such as and , where T-cell mediated cytotoxicity and antibody responses target thyroid-specific antigens like (Tg), (TPO), and the (TSHR). The interplay of and environmental triggers initiates a breakdown in , resulting in chronic inflammation and glandular damage. Hashimoto's thyroiditis, the most common cause of autoimmune , is characterized by the presence of anti-TPO antibodies (detected in over 90% of affected individuals) and anti-Tg antibodies (detected in 50–60% of affected individuals), which contribute to thyroid follicular cell destruction through and complement activation. Lymphocytic infiltration, predominantly involving CD4+ and CD8+ T cells, forms germinal centers within the thyroid stroma, leading to progressive and of thyroid tissue. This cell- and antibody-mediated immune attack destroys thyroid follicular cells, impairing hormone synthesis and release. Graves' disease, in contrast, features autoantibodies targeting the TSH receptor, including stimulating TSH receptor antibodies (TSAb) that mimic TSH action, binding to the receptor's conformational site and inducing cyclic AMP production to drive excessive thyroid hormone synthesis and glandular . Blocking TSH receptor antibodies (TBAb) inhibit TSH binding and can lead to in some cases, while neutral antibodies bind without functional effect, though their role remains under investigation. These antibodies arise from B-cell activation and T-cell help, perpetuating through sustained receptor stimulation. Atrophic thyroiditis represents a variant of , distinguished by marked gland atrophy and minimal enlargement, often progressing from the goitrous form due to extensive following chronic lymphocytic infiltration. Similar to Hashimoto's, it involves anti-TPO and anti-Tg antibodies, with T-cell mediated injury via cytokines like IL-17 from Th17 cells contributing to follicular cell and glandular shrinkage. In some cases, IgG4-positive plasma cells are prominent, linking it to and accelerated . Genetic factors play a crucial role in susceptibility to autoimmune thyroid diseases, with associations to (HLA) alleles such as HLA-DR3 and , which influence and T-cell recognition of thyroid autoantigens. Polymorphisms in the CTLA-4 gene, particularly the +49A/G variant, impair T-cell regulation by reducing inhibitory signaling, thereby promoting autoreactive lymphocyte proliferation and increasing risk for both Hashimoto's and . These genetic elements, accounting for up to 50% of , interact with environmental factors to initiate . Postpartum thyroiditis is an autoimmune condition occurring within the first year after delivery, often in women with preexisting thyroid autoantibodies, featuring an initial destructive thyrotoxic phase due to rapid release of preformed hormones from inflamed follicles, followed by a hypothyroid phase from depleted glandular reserves. The thyrotoxicosis typically emerges 1-3 months postpartum and lasts 1-3 months, driven by lymphocytic infiltration similar to , while hypothyroidism develops 3-6 months later, persisting for 4-6 months in many cases. This biphasic pattern reflects transient immune rebound post-pregnancy . Autoimmune thyroid diseases frequently overlap with other autoimmune disorders, such as , where shared genetic loci like and CTLA-4 contribute to polyautoimmunity, with up to 30% of patients developing thyroid autoimmunity. This clustering forms autoimmune polyendocrinopathy syndromes, highlighting common pathways in immune dysregulation.

Nutritional and environmental factors

Nutritional deficiencies play a significant role in thyroid pathology, particularly through inadequate intake of essential micronutrients required for hormone synthesis and metabolism. Iodine deficiency remains a primary cause of endemic goiter, where thyroid enlargement affects populations in iodine-poor regions, often leading to hypothyroidism due to insufficient thyroid hormone production despite compensatory glandular hypertrophy. In severe cases, this deficiency impairs neurodevelopment and increases susceptibility to other thyroid disorders. Conversely, excess iodine intake, such as from supplements or iodized products in previously deficient areas, can precipitate hyperthyroidism, known as Jod-Basedow phenomenon, by overwhelming the thyroid's regulatory mechanisms and inducing autonomous hormone release. Selenium deficiency further disrupts thyroid function by inhibiting the activity of iodothyronine deiodinases, enzymes critical for converting thyroxine (T4) to the active (T3). This impairment reduces peripheral thyroid hormone availability, potentially exacerbating in selenium-poor soils common in certain agricultural areas. Environmental contaminants like and thiocyanates, found in water supplies and tobacco smoke respectively, competitively block iodine uptake by the sodium-iodide in the , mimicking and elevating the risk of even in iodine-replete settings. Radiation exposure, particularly from nuclear accidents, heightens risk in children due to the thyroid's sensitivity to during development. For instance, post-Chernobyl studies show elevated incidence among those exposed under age 5, with risks persisting decades later. Dietary goitrogens, such as glucosinolates in (e.g., , ) and cyanogenic compounds in , interfere with iodine organification and thyroid hormone synthesis, contributing to goiter formation when consumed in large amounts without adequate iodine. Cooking mitigates much of this effect, but chronic high intake in staple-based diets can sustain thyroid enlargement. Geographic and climatic factors influence thyroid disease prevalence through variations in soil nutrient content and environmental exposures. Inland and high-altitude regions often exhibit higher rates of disorders due to lower in water and crops, while coastal areas benefit from marine iodine sources but may face excess from iodized salt programs. Tropical climates exacerbate issues via low-iodine staples like and millet, leading to endemic goiter in affected populations.

Thyroid dysfunction in pregnancy

During pregnancy, estrogen levels rise significantly, leading to an increase in thyroxine-binding globulin (TBG) concentrations, which elevates total thyroxine (T4) levels while free T4 remains stable. This physiological adaptation necessitates a 25-50% increase in maternal T4 production to maintain euthyroid free hormone levels and support fetal development. The thyroid gland's response involves heightened responsiveness to thyroid-stimulating hormone (TSH), ensuring adequate hormone synthesis amid increased renal clearance and distribution volume. Hypothyroidism during , whether overt or subclinical, poses substantial risks to maternal and fetal health. Untreated cases are associated with adverse outcomes including , , , , and postpartum hemorrhage. Fetal implications extend to neurodevelopmental deficits, such as reduced IQ and impaired cognitive function, due to insufficient availability during critical development phases. These risks underscore the importance of early detection and management to mitigate long-term consequences. Hyperthyroidism in pregnancy affects approximately 0.2-1.0% of cases, predominantly due to Graves' disease, which may flare in the first trimester before improving in the third due to immune modulation and high-output heart failure risks. Maternal complications include thyroid storm, heart failure, and exacerbated symptoms like tachycardia. A distinct entity, transient gestational thyrotoxicosis, arises from high human chorionic gonadotropin (hCG) levels stimulating the TSH receptor, typically resolving by 14-20 weeks without antithyroid antibodies. Differentiation from Graves' relies on clinical history and antibody testing to guide appropriate intervention. Postpartum thyroiditis, an autoimmune-mediated , occurs in 5-10% of women in the United States, often presenting with a hyperthyroid phase followed by . Incidence is higher in those with preexisting thyroid peroxidase antibodies or , reflecting underlying autoimmune predisposition. Most cases resolve within 12-18 months, though up to 20-30% may progress to permanent . Screening for dysfunction is recommended via serum TSH measurement in the first trimester for high-risk women, including those with a history of disease, autoimmune disorders, or . The American College of Obstetricians and Gynecologists (ACOG) advises against universal screening but supports targeted testing, with TSH reference ranges adjusted lower in (e.g., 0.1-2.5 mIU/L in the first trimester). The American Association (ATA) guidelines similarly emphasize trimester-specific thresholds to detect subclinical early. Fetal thyroid development begins around 12 weeks of gestation, when the gland starts producing thyroid hormones, though full maturation occurs near term and relies initially on maternal transfer of T4 across the placenta. Maternal thyroid-stimulating hormone receptor antibodies (TRAb) can cross the placenta, potentially inducing fetal hyperthyroidism in Graves' disease cases, with monitoring via ultrasound for goiter or tachycardia. This transplacental antibody transfer highlights the interplay between maternal autoimmune status and fetal thyroid function.

Diagnosis

Blood tests

Blood tests are essential for evaluating thyroid function and diagnosing thyroid diseases by measuring hormone levels and related markers in the serum. The (TSH) assay serves as the primary screening test due to its high sensitivity in detecting both primary and secondary hypothyroidism or hyperthyroidism. In primary thyroid disorders, TSH levels inversely reflect thyroid hormone production, while elevated TSH with low free thyroxine (FT4) indicates secondary hypothyroidism from pituitary dysfunction. Free T4 and free triiodothyronine (FT3) measurements provide direct assessments of active available to tissues, distinguishing them from total T4 and total T3, which include bound to carrier proteins like and may be influenced by factors such as or use. Free assays are preferred for accuracy in most clinical scenarios, as total levels can fluctuate with binding protein alterations without reflecting true function. Abnormal TSH prompts FT4 testing to confirm overt , with FT3 added if is suspected, as it correlates with symptoms like . Antithyroid antibodies help identify autoimmune etiologies of thyroid dysfunction. Thyroid peroxidase antibodies (anti-TPO) are the most common and strongly associated with , present in over 90% of cases, while thyroglobulin antibodies (anti-Tg) occur in about 60% and aid in confirming autoimmune . TSH receptor antibodies (TRAb), particularly thyroid-stimulating immunoglobulins, are specific for , detectable in 80-90% of patients and correlating with disease severity. These tests are recommended when autoimmune thyroiditis is suspected based on clinical features or elevated TSH. Serum calcitonin measurement is used for screening medullary thyroid carcinoma (MTC), particularly in patients with family history of or thyroid nodules suspicious for MTC. Basal calcitonin levels >100 pg/mL are highly suggestive of MTC or C-cell hyperplasia with high specificity. Thyroglobulin serves as a for monitoring differentiated recurrence after and radioactive iodine ablation. Undetectable levels post-treatment predict excellent response, while detectable levels (e.g., ≥0.2 ng/mL post-ablation) or rising levels suggest persistent or recurrent disease, though antithyroglobulin antibodies can interfere and require concurrent monitoring. Reference ranges for thyroid function tests vary by age and physiological state to avoid misdiagnosis. In older adults, TSH upper limits may extend to 4.5-6.0 mIU/L due to age-related changes, reducing of subclinical . During , trimester-specific ranges are critical; for instance, first-trimester TSH upper limit is approximately 2.5 mIU/L, reflecting hCG-mediated TSH suppression, with FT4 ranges adjusted for method-specific assays. These adjustments ensure accurate interpretation in contexts like subclinical , where mild TSH elevations may indicate early disease.

Imaging modalities

Imaging modalities play a crucial role in the evaluation of thyroid disease by providing structural and functional information to guide diagnosis and management. These non-invasive techniques help characterize thyroid nodules, assess glandular function, and detect extensions or metastases, often integrated with results such as levels to determine the need for further . is the initial imaging modality of choice for evaluating thyroid nodules due to its accessibility, lack of , and ability to assess multiple features. It characterizes nodules based on composition (solid, cystic, or mixed), , margins, , calcifications, and using Doppler to evaluate flow patterns, which can indicate benign or suspicious features. The American College of Radiology Thyroid Imaging Reporting and Data System (ACR TI-RADS) standardizes risk stratification by assigning points to ultrasound features—such as composition, , , margins, and echogenic foci—to categorize nodules into risk levels (TR1 to TR5), recommending for higher-risk nodules greater than specific size thresholds (e.g., TR5 nodules ≥1 cm). also evaluates cervical lymph nodes for suspicious characteristics like loss of fatty hilum, hyperechogenicity, or irregular borders, aiding in the detection of regional spread in . Nuclear medicine scans provide functional assessment of the thyroid gland. Radioiodine uptake scans, using or , measure thyroidal iodine avidity and distinguish hyperfunctioning "hot" nodules (rarely malignant, with 96-99% negative predictive value for cancer) from nonfunctioning "cold" nodules (80-90% benign but requiring further ). In , these scans typically show diffuse increased uptake throughout the gland, confirming autonomous hyperfunction. with pertechnetate offers a comparable functional with advantages of lower dose, shorter imaging time (within 30 minutes post-injection), and wider availability, particularly useful for assessing multinodular goiter or nodule autonomy. Computed tomography (CT) and (MRI) are employed for advanced structural evaluation, particularly when is limited. CT excels in delineating retrosternal goiter extension into the or assessing local invasion in larger masses, providing detailed cross-sectional images for preoperative planning. offers superior soft-tissue contrast without , making it preferable for evaluating invasion into adjacent structures like the trachea or in suspected . Positron emission tomography-computed tomography (PET-CT) using 18F-fluorodeoxyglucose (FDG) has become a standard for detecting metastatic differentiated thyroid cancer since the 2010s, especially in cases with elevated thyroglobulin but negative radioiodine scans, identifying non-iodine-avid lesions with high sensitivity (up to 89%). It is recommended by guidelines for staging persistent or recurrent disease and guiding therapy in advanced cases. A key limitation of radioiodine uptake scans, , CT, and PET-CT is , which necessitates careful consideration in vulnerable populations such as pregnant individuals, where these modalities are contraindicated unless essential.

Biopsy procedures

procedures are essential invasive methods for obtaining tissue samples from lesions, particularly nodules, to confirm or rule out when and blood tests suggest concern. These procedures primarily involve (FNA), which is the gold standard for cytological evaluation, often performed under guidance to target suspicious areas accurately. Fine-needle aspiration (FNA) entails inserting a thin needle (typically 25-27 gauge) into the to aspirate cells for cytological analysis, usually requiring multiple passes for adequate sampling. Indications for FNA include thyroid nodules greater than 1 cm in size with high-suspicion features, such as hypoechoic composition, irregular margins, microcalcifications, or taller-than-wide shape, as these carry a higher of . For nodules with intermediate suspicion, FNA is recommended if the nodule is at least 1 cm; low-suspicion nodules may warrant FNA if 1.5 cm or larger, while very low-suspicion spongiform nodules typically require evaluation only if exceeding 2 cm. The procedure is outpatient, quick (under 30 minutes), and performed by endocrinologists, radiologists, or cytopathologists trained in the technique. FNA results are classified using the for Reporting Thyroid Cytopathology, a standardized six-category framework that stratifies risk to guide management. The system, endorsed by major organizations, categorizes samples as follows:
CategoryDescriptionImplied Risk of (%)
INondiagnostic or unsatisfactory1–4
IIBenign0–3
IIIAtypia of undetermined significance (AUS) or Follicular lesion of undetermined significance (FLUS)5–15
IVFollicular or Suspicious for follicular 15–30
VSuspicious for 60–75
VI97–99
Categories I and III often necessitate repeat FNA, while V and VI typically prompt surgical intervention; II supports observation, and IV may require diagnostic . This classification improves diagnostic accuracy and reduces unnecessary surgeries. When FNA yields inadequate or nondiagnostic results (Bethesda I, occurring in 2–20% of cases depending on operator experience), core needle using a larger gauge (18–21) may be employed as an alternative to obtain histological tissue fragments, particularly for predominantly cystic or calcified nodules where cytology is limited. Core provides more architectural detail and higher adequacy rates (up to 95%) but is less sensitive for detecting papillary thyroid compared to FNA. It is reserved for cases where repeat FNA fails, and its use is guided by similar criteria as FNA. Complications from thyroid biopsy procedures are rare, occurring in less than 1% of cases overall, with most being minor and self-resolving. Common minor issues include or hemorrhage (0–6.4%), vasovagal reactions, and transient pain at the site; major complications such as , vocal cord , or significant are exceedingly uncommon (0.06–0.3%), especially with guidance and experienced operators. Post-procedure monitoring for 15–30 minutes is standard to address any immediate issues. Molecular testing on FNA samples has emerged since 2015 as an adjunct for risk stratification in indeterminate cytology (Bethesda ), analyzing mutations like BRAF V600E or RAS to refine malignancy probability. Tests such as the seven-gene panel (detecting BRAF, NRAS, , and others) or classifiers help identify low-risk nodules suitable for observation, reducing surgeries by 30–50% in select cases, though their long-term impact requires further validation. These are recommended after counseling on costs and limitations, particularly for nodules with clinical features favoring benignity. In the context of thyroid cancer diagnosis, biopsy procedures play a pivotal role in confirming , distinguishing benign from neoplastic lesions, and informing surgical planning, such as extent of , thereby avoiding overtreatment in up to 70% of biopsied nodules that prove benign.

Management

Pharmacological treatments

Pharmacological treatments for thyroid disease primarily target the underlying hormonal imbalances in and , as well as specific etiologies like and post-cancer suppression. , a synthetic form of thyroxine (T4), is the cornerstone therapy for , replacing deficient thyroid hormone to restore euthyroidism. The initial adult dose is typically 1.6 mcg/kg body weight daily, adjusted based on clinical response and . Therapy aims to normalize serum (TSH) levels, with monitoring recommended every 6-12 months once stable, or more frequently after dose changes. Full replacement often requires 1.5-1.8 mcg/kg daily, with doses exceeding 200 mcg rarely needed. For , antithyroid drugs inhibit thyroid hormone synthesis and are first-line for conditions like . Methimazole is preferred due to its once-daily dosing and lower hepatotoxicity risk compared to (PTU), which is reserved for first-trimester or methimazole intolerance. Both drugs carry risks of , occurring in 0.03-0.5% of patients, with PTU more frequently associated with severe potentially requiring transplantation. Routine liver function monitoring is essential, particularly in the first months of therapy. Beta-blockers, such as , provide rapid symptom relief by blocking adrenergic effects, controlling , , and anxiety regardless of the cause. Nonselective agents like are recommended at , especially in symptomatic or elderly patients, with dosing titrated to heart rate. In thyroiditis, particularly subacute or destructive forms, corticosteroids like reduce inflammation and alleviate , with typical regimens starting at 40-60 mg daily and tapering over 4-6 weeks. Lithium serves as an alternative for hyperthyroid phases in certain thyroiditis cases or when antithyroid drugs are contraindicated, inhibiting thyroid hormone release at doses of 300-900 mg daily, though its use requires close monitoring for renal and thyroid effects. For patients with post-thyroidectomy, suppressive aims to maintain TSH within or below the normal reference range to inhibit potential recurrence, depending on risk stratification and response to , often requiring higher doses than replacement —approximately 2.1-2.5 mcg/kg daily initially, adjusted accordingly. Long-term monitoring includes annual TSH assessment and evaluation due to risks of from prolonged suppression. Emerging adjunctive use of cholestyramine, a , binds excess circulating in the gut, accelerating their clearance in refractory . Recent studies demonstrate faster T3 and T4 reductions when added to standard therapy, with doses of 4-16 g daily divided, particularly beneficial in thyrotoxicosis unresponsive to antithyroid drugs.

Surgical options

Surgical options for disease primarily involve , the removal of part or all of the gland, which is indicated when medical management fails or for definitive treatment of certain conditions. This procedure is commonly performed for , large symptomatic goiters, suspicious nodules, and refractory such as in or . should be performed by high-volume surgeons (≥25 cases per year) to minimize complications. Types of thyroidectomy include total thyroidectomy, which removes the entire gland and is standard for higher-risk differentiated thyroid cancers, bilateral disease, or larger tumors; subtotal or near-total thyroidectomy, which leaves a small remnant of thyroid tissue (typically 1-2 grams) to potentially preserve parathyroid function in cases like Graves' disease; and lobectomy (hemithyroidectomy), which removes one lobe and is preferred for low-risk papillary thyroid cancers less than 2 cm without extrathyroidal extension or suspicious lymph nodes, or for unilateral benign nodules. Prophylactic central neck dissection is not recommended for clinically node-negative T1-T2 tumors. The choice depends on the underlying pathology, with total removal preferred for malignancy to facilitate cancer staging and reduce recurrence risk. Pre-operative preparation emphasizes achieving a euthyroid state in hyperthyroid patients using antithyroid drugs and iodine (e.g., Lugol's solution) to decrease vascularity and prevent . Vocal cord assessment via is recommended to baseline function, and serum calcium levels are monitored to identify baseline parathyroid status. Conventional open thyroidectomy uses a horizontal collar incision in the , but minimally invasive techniques have advanced since 2010, including video-assisted thyroidectomy (VAT) with a 1.5-2 cm incision and endoscopic visualization for nodules under 3 cm, and robotic approaches such as transaxillary or bilateral axillo-breast methods that avoid scars by accessing via the chest, offering enhanced precision through 3D imaging. These techniques are suitable for smaller tumors with good mobility but are contraindicated in large goiters or prior surgery. Complications, though reduced with experienced surgeons, include leading to (transient in up to 33%, permanent in 1-2%), recurrent laryngeal nerve injury causing hoarseness or vocal cord paralysis (1-2% permanent risk), superior laryngeal nerve damage affecting voice pitch (0-58% incidence), and hemorrhage (0.3-1%, potentially requiring urgent reoperation if airway compromise occurs). Intraoperative monitoring and parathyroid autofluorescence aid in . Post-operatively, patients undergoing total require lifelong replacement (typically 1-2 mcg/kg/day) to maintain euthyroidism, with TSH suppression in cancer cases to inhibit growth. Calcium levels are closely monitored, with supplements or for ; discharge requires stable calcium (≥7.8 mg/dL) and PTH ≥15 pg/mL at 1 hour post-surgery. For cancer, informs staging using systems like AGES or MACIS, guiding further management. Patients should avoid strenuous activity for 10-14 days, and scars typically fade within a year.

Radioactive iodine therapy

Radioactive iodine therapy, utilizing (I-131), is a targeted treatment for managing and certain s by selectively destroying abnormal tissue. Administered orally as , I-131 is absorbed into the bloodstream and preferentially taken up by follicular cells due to the gland's natural iodine-concentrating mechanism. This therapy is particularly effective for conditions like and differentiated carcinoma, offering a non-surgical option that leverages the 's for precise delivery. For , preparation preferably uses recombinant human (rhTSH) stimulation rather than hormone withdrawal. The primary mechanism of action involves the beta emissions from I-131 decay, which release high-energy electrons that damage the DNA of thyroid follicular cells, leading to cell death and tissue ablation. Once internalized, I-131 emits beta particles with a short range (approximately 2 mm in tissue), minimizing damage to surrounding structures while effectively targeting iodine-avid cells. Gamma emissions, also produced, allow for imaging but contribute less to the therapeutic effect. This selective cytotoxicity spares non-thyroid tissues that do not concentrate iodine. In , particularly , I-131 ablation aims to reduce thyroid hormone production by destroying overactive follicular cells. Dosing strategies include fixed doses (typically 10-15 mCi) or calculated doses based on thyroid size, radioiodine uptake, and desired (often 80-120 Gy to the ). Fixed dosing is simpler and widely used, while calculated approaches may optimize efficacy but require additional . Efficacy is high, with 80-90% of patients achieving remission (euthyroidism or ) after a single dose, though 10-20% may need repeat treatment. For , post-surgical remnant with I-131 eliminates microscopic tissue left after , reducing recurrence risk in differentiated cancers. Dosing is individualized by risk, with a typical low- to intermediate-risk dose of 30 mCi (1.1 GBq) achieving successful in 80-90% of cases. Higher doses (100-150 mCi) may be used for in higher-risk scenarios to target potential metastases. This complements surgical options by addressing residual disease non-invasively. Common side effects include sialadenitis (inflammation of salivary glands, affecting 15-30% of patients and causing dry mouth), transient nausea, and altered taste, often resolving within weeks. Gonadal exposure can temporarily reduce fertility, with recommendations to delay conception for at least 6 months post-therapy; no fertility impact is expected at typical doses. Therapy is absolutely contraindicated in pregnancy due to risks of fetal thyroid ablation and developmental harm, requiring confirmed non-pregnancy status beforehand. Follow-up after involves whole-body scans 7-10 days post-administration to assess uptake and distribution, confirming success. Long-term monitoring includes serial levels (ideally undetectable in athyreotic patients) and stimulated scans at 6-12 months to detect recurrence, guiding further management. For iodine-avid tumors refractory to standard I-131, alternatives include external beam radiation, targeted therapies like inhibitors, or clinical trials with novel radioisotopes, though these are less established.

Epidemiology

Global prevalence and distribution

Thyroid diseases encompass a range of conditions, including , , goiter, and , with varying global prevalence influenced by iodine nutrition and healthcare access. In iodine-sufficient regions, the prevalence of is estimated at 4-5%, with overt cases around 0.3-0.5% and subclinical forms comprising the majority. Women are disproportionately affected, with a female-to-male of approximately 5-10:1, attributed to autoimmune etiologies like . affects 0.2-1.4% of the global population, predominantly in iodine-replete areas, where accounts for 60-80% of cases. Goiter, often resulting from , has a global prevalence of approximately 5% among school-aged children, though rates exceed 20% in endemic regions of and according to assessments. Iodine supplementation programs, such as universal salt iodization, have significantly reduced goiter prevalence in developing nations; for instance, global estimates indicate a decline from 20-60% in the 1960s to under 10% in many iodine-deficient areas by the 2020s. represents 1-2% of all malignancies worldwide, with an incidence of about 13.5 per 100,000 in high-resource settings, showing historical annual increases of up to 3% driven by improved detection, though recent trends indicate stabilization or slight declines in some populations. Regional variations highlight the impact of iodine status and socioeconomic factors; iodine-deficient areas in and parts of report higher goiter and rates, while excess iodine in regions like parts of correlates with elevated . Underdiagnosis remains prevalent in low-resource settings, where limited access to thyroid function testing contributes to an estimated 5% or more of cases going undetected, exacerbating morbidity in vulnerable populations.

Risk factors and demographics

Thyroid disease exhibits significant variations across demographic groups, with age and playing prominent roles in susceptibility. Hypothyroidism prevalence increases with advancing age, peaking after 60 years due to the cumulative effects of autoimmune processes and other age-related factors. In contrast, incidence typically peaks between ages 20 and 55, particularly among women during reproductive years, reflecting hormonal influences on thyroid cell proliferation. Women face a substantially higher risk for most thyroid disorders, with primary occurring up to 8-9 times more frequently than in men, attributed to sex-specific immune responses and hormonal fluctuations. This gender disparity extends to autoimmune thyroid conditions like and , where female predominance is evident across populations. Ethnic and racial differences further modulate risk profiles. Autoimmune thyroid diseases, such as , show higher prevalence among Caucasians, with rates estimated at approximately 5% in this group, linked to genetic predispositions in immune regulation. Conversely, iodine deficiency-related goiter remains more prevalent in n populations, particularly in regions like South-East where historical deficiencies affected over 100 million individuals, despite iodization efforts. These patterns highlight how environmental iodine availability interacts with ethnic genetic backgrounds to influence disease susceptibility. Genetic factors contribute substantially to thyroid disease risk, with family history serving as a key indicator of hereditary predisposition across various disorders. First-degree relatives of affected individuals have elevated risks for autoimmune thyroiditis and due to shared polygenic traits. Emerging research on polygenic risk scores (PRS) underscores this complexity; for instance, PRS incorporating variants related to immunity and predict higher risk, particularly under nutritional stressors like low iodine intake. Similarly, PRS for susceptibility, derived from multiple SNPs, have demonstrated associations in diverse cohorts, emphasizing the polygenic architecture of these conditions. Lifestyle elements also heighten vulnerability to specific manifestations of thyroid disease. Cigarette smoking is a well-established risk factor that exacerbates Graves' orbitopathy, increasing its odds by up to 7.7-fold through mechanisms involving oxidative stress and immune modulation. Smokers with Graves' disease experience more severe ophthalmopathy and poorer treatment responses, underscoring the need for smoking cessation in management. Obesity correlates with increased thyroid nodule formation, with higher body mass index associated with greater nodule multiplicity and a modest elevation in malignancy risk, possibly via insulin resistance and inflammatory pathways. These modifiable factors interact with genetic and demographic risks to amplify disease burden. Socioeconomic conditions and environmental exposures influence thyroid disease through disparities in preventive measures and historical events. Limited access to iodized salt in low- and middle-income households perpetuates disorders like goiter, with utilization rates varying by education, wealth, and rural residence. Ionizing radiation exposure, as seen in cohorts affected by the 1986 Chernobyl accident, dramatically elevates risk, especially among children under 5 years at exposure, with excess relative risks persisting decades later. Such events highlight how socioeconomic barriers to monitoring and can exacerbate vulnerabilities in affected populations.

References

  1. https://medlineplus.gov/thyroiddiseases.html
  2. https://www.ncbi.nlm.nih.gov/books/NBK550859/
  3. https://www.sciencedirect.com/science/article/pii/S0140673624016143
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC6822815/
  5. https://pubmed.ncbi.nlm.nih.gov/37847271/
  6. https://www.mayoclinic.org/diseases-conditions/hypothyroidism/symptoms-causes/syc-20350284
  7. https://www.mayoclinic.org/diseases-conditions/hyperthyroidism/symptoms-causes/syc-20373659
  8. https://www.ncbi.nlm.nih.gov/books/NBK470452/
  9. https://www.ncbi.nlm.nih.gov/books/NBK551659/
  10. https://www.ncbi.nlm.nih.gov/books/NBK560666/
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC5739519/
  12. https://www.ncbi.nlm.nih.gov/books/NBK500006/
  13. https://www.ncbi.nlm.nih.gov/books/NBK285545/
  14. https://www.ncbi.nlm.nih.gov/books/NBK285566/
  15. https://lpi.oregonstate.edu/mic/minerals/iodine
  16. https://www.niddk.nih.gov/health-information/endocrine-diseases/hypothyroidism
  17. https://www.ncbi.nlm.nih.gov/books/NBK545193/
  18. https://www.ncbi.nlm.nih.gov/books/NBK558913/
  19. https://www.thyroid.org/hyperthyroidism/
  20. https://www.niddk.nih.gov/health-information/endocrine-diseases/hyperthyroidism
  21. https://www.thyroid.org/graves-disease/
  22. https://www.niddk.nih.gov/health-information/endocrine-diseases/graves-disease
  23. https://my.clevelandclinic.org/health/diseases/12625-goiter
  24. https://www.ncbi.nlm.nih.gov/books/NBK562161/
  25. https://emedicine.medscape.com/article/849159-overview
  26. https://www.thyroid.org/thyroiditis/
  27. https://www.ncbi.nlm.nih.gov/books/NBK279084/
  28. https://www.thyroid.org/thyroid-nodules/
  29. https://www.aafp.org/pubs/afp/issues/2013/0801/p193.html
  30. https://www.mayoclinic.org/diseases-conditions/goiter/symptoms-causes/syc-20351829
  31. https://jamanetwork.com/journals/jamasurgery/fullarticle/396812
  32. https://www.ncbi.nlm.nih.gov/books/NBK285569/
  33. https://www.ncbi.nlm.nih.gov/books/NBK448195/
  34. http://www.thyroid.org/thyroidguidelines/file/THY_2010_0417.pdf
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC11021553/
  36. https://www.ncbi.nlm.nih.gov/books/NBK535422/
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC2879398/
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC3575959/
  39. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2020.565371/full
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC6405443/
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC5368126/
  42. https://jn.nutrition.org/article/S0022-3166%2824%2901076-9/abstract
  43. https://pubmed.ncbi.nlm.nih.gov/39419352/
  44. https://www.cancer.org/cancer/types/thyroid-cancer/about/what-is-thyroid-cancer.html
  45. https://www.cancer.gov/types/thyroid/hp/thyroid-treatment-pdq
  46. https://www.cancer.org/cancer/types/thyroid-cancer/causes-risks-prevention/risk-factors.html
  47. https://www.cancer.gov/types/thyroid/patient/thyroid-treatment-pdq
  48. https://www.cancer.org/cancer/types/thyroid-cancer/detection-diagnosis-staging/staging.html
  49. https://www.cancer.org/cancer/types/thyroid-cancer/detection-diagnosis-staging/survival-rates.html
  50. https://www.mayoclinic.org/diseases-conditions/thyroid-cancer/symptoms-causes/syc-20354161
  51. https://www.cancer.gov/news-events/cancer-currents-blog/2023/selpercatinib-ret-lung-medullary-thyroid
  52. https://www.thyroid.org/new-ata-guidelines-adult-patients-differentiated-thyroid-cancer/
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC6661016/
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC9934045/
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC1741517/
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC2723027/
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC11597692/
  58. https://pmc.ncbi.nlm.nih.gov/articles/PMC161685/
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC7005931/
  60. https://pmc.ncbi.nlm.nih.gov/articles/PMC2134787/
  61. https://pmc.ncbi.nlm.nih.gov/articles/PMC2818066/
  62. https://pubmed.ncbi.nlm.nih.gov/16557537/
  63. https://pmc.ncbi.nlm.nih.gov/articles/PMC8224170/
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC7650809/
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC7047075/
  66. https://www.ncbi.nlm.nih.gov/books/NBK544277/
  67. https://pubmed.ncbi.nlm.nih.gov/38870258/
  68. https://pmc.ncbi.nlm.nih.gov/articles/PMC12040987/
  69. https://pmc.ncbi.nlm.nih.gov/articles/PMC5318340/
  70. https://pmc.ncbi.nlm.nih.gov/articles/PMC7151575/
  71. https://pubmed.ncbi.nlm.nih.gov/38295777/
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC3824811/
  73. https://pubmed.ncbi.nlm.nih.gov/38483545/
  74. https://pubmed.ncbi.nlm.nih.gov/36963756/
  75. https://pmc.ncbi.nlm.nih.gov/articles/PMC6738237/
  76. https://pmc.ncbi.nlm.nih.gov/articles/PMC11816041/
  77. https://pmc.ncbi.nlm.nih.gov/articles/PMC5422478/
  78. https://www.ncbi.nlm.nih.gov/books/NBK459262/
  79. https://pmc.ncbi.nlm.nih.gov/articles/PMC3710642/
  80. https://www.ncbi.nlm.nih.gov/books/NBK285557/
  81. https://pmc.ncbi.nlm.nih.gov/articles/PMC5047290/
  82. https://pmc.ncbi.nlm.nih.gov/articles/PMC3539254/
  83. https://pubmed.ncbi.nlm.nih.gov/26361259/
  84. https://pmc.ncbi.nlm.nih.gov/articles/PMC8049926/
  85. https://pmc.ncbi.nlm.nih.gov/articles/PMC2244911/
  86. https://pmc.ncbi.nlm.nih.gov/articles/PMC3400896/
  87. https://pmc.ncbi.nlm.nih.gov/articles/PMC1808990/
  88. https://www.ncbi.nlm.nih.gov/books/NBK557646/
  89. https://www.ncbi.nlm.nih.gov/books/NBK278999/
  90. https://pmc.ncbi.nlm.nih.gov/articles/PMC5507951/
  91. https://pmc.ncbi.nlm.nih.gov/articles/PMC7988207/
  92. https://pubmed.ncbi.nlm.nih.gov/34595540/
  93. https://www.ncbi.nlm.nih.gov/books/NBK285556/
  94. https://pubmed.ncbi.nlm.nih.gov/11396708/
  95. https://pubmed.ncbi.nlm.nih.gov/1384621/
  96. https://pmc.ncbi.nlm.nih.gov/articles/PMC5307254/
  97. https://pmc.ncbi.nlm.nih.gov/articles/PMC6035476/
  98. https://pmc.ncbi.nlm.nih.gov/articles/PMC4829993/
  99. https://pmc.ncbi.nlm.nih.gov/articles/PMC4399027/
  100. https://pmc.ncbi.nlm.nih.gov/articles/PMC10118869/
  101. https://pmc.ncbi.nlm.nih.gov/articles/PMC7282437/
  102. https://www.ncbi.nlm.nih.gov/books/NBK605491/
  103. https://pmc.ncbi.nlm.nih.gov/articles/PMC7806590/
  104. https://pmc.ncbi.nlm.nih.gov/articles/PMC10762831/
  105. https://www.thyroid.org/hypothyroidism-in-pregnancy/
  106. https://www.nejm.org/doi/pdf/10.1056/NEJM199410203311608
  107. https://www.aafp.org/pubs/afp/issues/2014/0215/p273.html
  108. https://www.ncbi.nlm.nih.gov/books/NBK538485/
  109. https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.18088
  110. https://www.ncbi.nlm.nih.gov/books/NBK279107/
  111. https://www.thyroid.org/hyperthyroidism-in-pregnancy/
  112. https://www.btf-thyroid.org/gestational-transient-thyrotoxicosis-in-pregnancy
  113. https://www.thyroid.org/postpartum-thyroiditis/
  114. https://www.thyroid.org/wp-content/uploads/patients/brochures/Postpartum_Thyroiditis_brochure.pdf
  115. https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2020/06/thyroid-disease-in-pregnancy
  116. https://www.liebertpub.com/doi/10.1089/thy.2016.0457
  117. https://vivo.colostate.edu/hbooks/pathphys/endocrine/thyroid/thyroid_preg.html
  118. https://pmc.ncbi.nlm.nih.gov/articles/PMC4166486/
  119. https://www.thyroid.org/patient-thyroid-information/ct-for-patients/august-2018/vol-11-issue-8-p-3-4/
  120. https://www.epocrates.com/online/diseases/1121/thyroid-function-testing
  121. https://www.thyroid.org/thyroid-function-tests/
  122. https://columbiasurgery.org/thyroid/thyroid-function-tests
  123. https://emedicine.medscape.com/article/120937-workup
  124. https://pmc.ncbi.nlm.nih.gov/articles/PMC4490627/
  125. https://academic.oup.com/jes/article/7/9/bvad102/7236755
  126. https://www.thyroid.org/patient-thyroid-information/ct-for-patients/february-2025/vol-18-issue-2-p-7-8/
  127. https://pmc.ncbi.nlm.nih.gov/articles/PMC4739132/
  128. https://www.acr.org/Clinical-Resources/Clinical-Tools-and-Reference/Reporting-and-Data-Systems/TI-RADS
  129. https://doi.org/10.1007/s00259-019-04472-8
  130. https://www.ncbi.nlm.nih.gov/books/NBK599130/
  131. https://jnccn.org/view/journals/jnccn/20/8/article-p925.xml
  132. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1470
  133. https://www.thyroid.org/fna-thyroid-nodules/
  134. https://www.e-enm.org/journal/view.php?number=2379
  135. https://www.ncbi.nlm.nih.gov/books/NBK539808/
  136. https://www.thyroid.org/patient-thyroid-information/what-are-thyroid-problems/q-and-a-tsh-thyroid-stimulating-hormone/
  137. https://www.aafp.org/pubs/afp/issues/2021/0515/p605.html
  138. https://www.liebertpub.com/doi/full/10.1089/thy.2016.0229
  139. https://www.thyroid.org/patient-thyroid-information/ct-for-patients/february-2020/vol-13-issue-2-p-5-6/
  140. https://www.ncbi.nlm.nih.gov/books/NBK549828/
  141. https://www.uptodate.com/contents/beta-blockers-in-the-treatment-of-hyperthyroidism
  142. https://www.liebertpub.com/doi/10.1089/thy.2016.0229
  143. https://www.aafp.org/pubs/afp/issues/2016/0301/p363.html
  144. https://pmc.ncbi.nlm.nih.gov/articles/PMC4575726/
  145. https://www.e-enm.org/journal/view.php?number=2523
  146. https://www.thyroid.org/patient-thyroid-information/ct-for-patients/vol-7-issue-5/vol-7-issue-5-p-6-7/
  147. https://www.mdpi.com/2673-396X/6/3/30
  148. https://pmc.ncbi.nlm.nih.gov/articles/PMC11401596/
  149. https://www.mayoclinic.org/tests-procedures/thyroidectomy/about/pac-20385195
  150. https://www.ncbi.nlm.nih.gov/books/NBK563279/
  151. https://www.ncbi.nlm.nih.gov/books/NBK285564/
  152. https://pmc.ncbi.nlm.nih.gov/articles/PMC10251895/
  153. https://www.ncbi.nlm.nih.gov/books/NBK557741/
  154. https://www.ncbi.nlm.nih.gov/books/NBK580567/
  155. https://pubmed.ncbi.nlm.nih.gov/22936505/
  156. https://pmc.ncbi.nlm.nih.gov/articles/PMC3336179/
  157. https://pmc.ncbi.nlm.nih.gov/articles/PMC4803554/
  158. https://www.e-enm.org/journal/view.php?number=2536
  159. https://pmc.ncbi.nlm.nih.gov/articles/PMC5040037/
  160. https://jnm.snmjournals.org/content/63/6/15N
  161. https://geiselmed.dartmouth.edu/radiology/wp-content/uploads/sites/47/2024/09/Radioactive-Iodine-Therapy-in-Differentiated-Thyroid-Cancer.pdf
  162. https://pubmed.ncbi.nlm.nih.gov/28742421/
  163. https://pmc.ncbi.nlm.nih.gov/articles/PMC6306449/
  164. https://jnm.snmjournals.org/content/53/10/1633
  165. https://pmc.ncbi.nlm.nih.gov/articles/PMC11046343/
  166. https://www.e-enm.org/journal/view.php?doi=10.3803/enm.2014.29.1.33
  167. https://jnm.snmjournals.org/content/42/10/1470
  168. https://jnm.snmjournals.org/content/55/9/1485
  169. https://ajronline.org/doi/10.2214/AJR.19.22626
  170. https://www.nature.com/articles/nrendo.2018.18
  171. https://www.uptodate.com/contents/disorders-that-cause-hyperthyroidism
  172. https://www.who.int/publications/i/item/WHO-NMH-NHD-EPG-14.5
  173. https://academic.oup.com/ejendo/article/185/1/R13/6654349
  174. https://seer.cancer.gov/statfacts/html/thyro.html
  175. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2025/2025-cancer-facts-and-figures-acs.pdf
  176. https://www.nature.com/articles/s41598-020-80248-7
  177. https://www.sciencedirect.com/science/article/pii/S266639612400044X
  178. https://pmc.ncbi.nlm.nih.gov/articles/PMC3077966/
  179. https://pmc.ncbi.nlm.nih.gov/articles/PMC10071442/
  180. https://pmc.ncbi.nlm.nih.gov/articles/PMC4426893/
  181. https://www.who.int/publications/i/item/9290221798
  182. https://pmc.ncbi.nlm.nih.gov/articles/PMC10808215/
  183. https://pmc.ncbi.nlm.nih.gov/articles/PMC8457978/
  184. https://pmc.ncbi.nlm.nih.gov/articles/PMC7084156/
  185. https://pubmed.ncbi.nlm.nih.gov/10614913/
  186. https://pmc.ncbi.nlm.nih.gov/articles/PMC3357079/
  187. https://pmc.ncbi.nlm.nih.gov/articles/PMC10305406/
  188. https://pmc.ncbi.nlm.nih.gov/articles/PMC11547564/
  189. https://pubmed.ncbi.nlm.nih.gov/12373328/
Add your contribution
Related Hubs
User Avatar
No comments yet.